San Rafael, CA, United States of America

Saeed Moshashaee

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 4.0

ph-index = 1


Location History:

  • San Rafael, CA (US) (2019 - 2022)
  • Novato, CA (US) (2022)

Company Filing History:


Years Active: 2019-2022

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Saeed Moshashaee: Innovator in Therapeutic Enzyme Research

Introduction

Saeed Moshashaee is a prominent inventor based in San Rafael, CA (US). He has made significant contributions to the field of therapeutic lysosomal enzyme fusion proteins. With a total of 4 patents, his work focuses on innovative solutions for treating lysosomal storage diseases.

Latest Patents

Moshashaee's latest patents include groundbreaking research on targeted therapeutic lysosomal enzyme fusion proteins. This patent relates to therapeutic lysosomal enzyme fusion proteins that are useful for treating lysosomal storage diseases. It also covers liquid formulations comprising such fusion proteins and associated methods for treating these diseases in mammals. Another notable patent is for TPP-1 formulations and methods for treating CLN2 disease. This patent discloses formulations comprising recombinant human tripeptidyl peptidase-1 (rhTPP1) for various administration routes. The methods outlined are effective in halting the progression of CLN2 disease and may be used to treat subjects with CLN2 or a family history of the disease.

Career Highlights

Moshashaee is currently associated with BioMarin Pharmaceutical Inc., where he continues to advance his research in therapeutic applications. His work has been instrumental in developing treatments that address critical health issues related to lysosomal storage diseases.

Collaborations

He collaborates with notable colleagues such as Thomas Lester and Augustus O Okhamafe, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Saeed Moshashaee's contributions to the field of therapeutic enzyme research are noteworthy. His innovative patents and ongoing work at BioMarin Pharmaceutical Inc. highlight his commitment to improving treatments for lysosomal storage diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…